{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:43:10Z","timestamp":1791027790070,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Commission: Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency (Cell-PID)","award":["HEALTH F5-2010-261387"],"award-info":[{"award-number":["HEALTH F5-2010-261387"]}]},{"name":"Italian Telethon Foundation"},{"name":"Fondazione Roma"},{"name":"Italian Ministry of Research and University (MIUR)"},{"DOI":"10.13039\/501100000781","name":"European Research Council (ERC)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.coi.2012.07.012","type":"journal-article","created":{"date-parts":[[2012,8,18]],"date-time":"2012-08-18T11:15:41Z","timestamp":1345288541000},"page":"585-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Gene therapy for primary immunodeficiencies: Part 2"],"prefix":"10.1016","volume":"24","author":[{"given":"Alessandro","family":"Aiuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Seger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Cavazzana-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2012.07.012_bib0005","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jaci.2011.04.030","article-title":"Gene therapy for primary adaptive immune deficiencies","volume":"127","author":"Fischer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/ACI.0b013e32833fea85","article-title":"Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency","volume":"10","author":"Ferrua","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0015_1","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott\u2013Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0020_1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to Evi1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/asheducation-2009.1.682","article-title":"Ten years of gene therapy for primary immune deficiencies","author":"Aiuti","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.coi.2012.07.012_bib0030","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/mt.2012.93","article-title":"Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy","volume":"20","author":"Corrigan-Curay","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0035_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.mt.6300341","article-title":"Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of Foxp3","volume":"16","author":"Allan","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0040","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood-2004-08-3269","article-title":"SAP controls the cytolytic activity of CD8+ T cells against ebv-infected cells","volume":"105","author":"Dupre","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04302.x","article-title":"Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management","volume":"163","author":"Gholam","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/mt.2010.259","article-title":"Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders","volume":"19","author":"Sather","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0055","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/leu.2010.140","article-title":"Correction of B-cell development in btk-deficient mice using lentiviral vectors with codon-optimized human btk","volume":"24","author":"Ng","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.coi.2012.07.012_bib0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nri2724","article-title":"Wasp: a key immunological multitasker","volume":"10","author":"Thrasher","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0065","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1182\/blood-2008-12-115253","article-title":"Recent advances in understanding the pathophysiology of Wiskott\u2013Aldrich syndrome","volume":"113","author":"Bosticardo","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0070","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1182\/blood-2009-09-239087","article-title":"X-linked thrombocytopenia (XLT) due to was mutations: clinical characteristics, long-term outcome, and treatment options","volume":"115","author":"Albert","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0075_1","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott\u2013Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980\u20132009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2012.31","article-title":"Outcomes following hematopoietic cell transplantation for Wiskott\u2013Aldrich syndrome","author":"Shin","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2012.07.012_bib0085","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/mp200132u","article-title":"Development of novel efficient sin vectors with improved safety features for Wiskott\u2013Aldrich syndrome stem cell based gene therapy","volume":"8","author":"Avedillo Diez","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.coi.2012.07.012_bib0090","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrg2985","article-title":"Ex vivo gene transfer and correction for cell-based therapies","volume":"12","author":"Naldini","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.coi.2012.07.012_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/14712598.8.2.181","article-title":"Development of lentiviral gene therapy for Wiskott\u2013Aldrich syndrome","volume":"8","author":"Galy","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ymthe.2004.08.008","article-title":"Lentiviral vector-mediated gene transfer in T cells from Wiskott\u2013Aldrich syndrome patients leads to functional correction","volume":"10","author":"Dupre","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.17.303","article-title":"Efficacy of gene therapy for Wiskott\u2013Aldrich syndrome using a WAS promoter\/cDNA-containing lentiviral vector and nonlethal irradiation","volume":"17","author":"Dupre","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.gt.3302863","article-title":"Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from was patients","volume":"14","author":"Charrier","year":"2007","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0115","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2009.31","article-title":"Evidence for long-term efficacy and safety of gene therapy for Wiskott\u2013Aldrich syndrome in preclinical models","volume":"17","author":"Marangoni","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0120","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jaci.2011.03.030","article-title":"Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott\u2013Aldrich syndrome","volume":"127","author":"Bosticardo","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0125","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/mt.2008.43","article-title":"Improvement of migratory defects in a murine model of Wiskott\u2013Aldrich syndrome gene therapy","volume":"16","author":"Blundell","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0130","article-title":"Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott\u2013Aldrich syndrome","author":"Catucci","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0135","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1182\/blood-2011-03-340711","article-title":"Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott\u2013Aldrich syndrome","volume":"119","author":"Astrakhan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0140_1","article-title":"Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott\u2013Aldrich syndrome","author":"Scaramuzza","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/hum.2010.060","article-title":"Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application","volume":"22","author":"Merten","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2008.03644.x","article-title":"Special article: Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry","volume":"152","author":"Jones","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0155","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/blood-2009-07-231498","article-title":"A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil nadph oxidase activity","volume":"114","author":"Matute","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.coi.2012.07.012_bib0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2007.09.008","article-title":"Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an italian multicenter study","volume":"126","author":"Martire","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2012.07.012_bib0170","first-page":"334","article-title":"Chronic granulomatous disease: recent advances in pathophysiology and treatment","volume":"68","author":"Seger","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/INF.0b013e3181f13b23","article-title":"Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France","volume":"30","author":"Beaute","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.coi.2012.07.012_bib0180","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","article-title":"Residual NADPH oxidase and survival in chronic granulomatous disease","volume":"363","author":"Kuhns","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/mt.2010.232","article-title":"Gene therapy of chronic granulomatous disease: the engraftment dilemma","volume":"19","author":"Grez","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0190","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for x-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0195","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for x-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00044.2005","article-title":"The nox family of ros-generating NADPH oxidases: physiology and pathophysiology","volume":"87","author":"Bedard","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.coi.2012.07.012_bib0205","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.coi.2012.07.012_bib0210_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0215_1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/gt.2011.65","article-title":"Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease","volume":"18","author":"Barde","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.coi.2012.07.012_bib0220","doi-asserted-by":"crossref","first-page":"58ra84","DOI":"10.1126\/scitranslmed.3001522","article-title":"Identification of hematopoietic stem cell-specific miRNAs enables gene therapy of globoid cell leukodystrophy","volume":"2","author":"Gentner","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0225","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1172\/JCI25112","article-title":"Defective regulatory and effector T cell functions in patients with Foxp3 mutations","volume":"116","author":"Bacchetta","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2012.07.012_bib0230","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMc0907093","article-title":"Foxp3 forkhead domain mutation and regulatory T cells in the ipex syndrome","volume":"361","author":"d\u2019Hennezel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0235","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity","volume":"3","author":"Barzaghi","year":"2012","journal-title":"Front Immun"},{"key":"10.1016\/j.coi.2012.07.012_bib0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2012.07.012_bib0245","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2009-02-206359","article-title":"Selective engraftment of donor CD4+25high Foxp3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation","volume":"113","author":"Seidel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0250","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1182\/blood-2009-04-214593","article-title":"Wild-type Foxp3 is selectively active in CD4+CD25(hi) regulatory T cells of healthy female carriers of different FOXP3 mutations","volume":"114","author":"Di Nunzio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0255","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.coi.2012.07.012_bib0260","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.coi.2012.07.012_bib0265","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement","volume":"8","author":"Aiuti","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2012.07.012_bib0270","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?","volume":"126","author":"Gennery","year":"2010","journal-title":"J Allergy Clin Immunol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791512001215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791512001215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:27:49Z","timestamp":1760603269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791512001215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0952791512001215"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2012.07.012","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for primary immunodeficiencies: Part 2","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2012.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}